References
- World Health Orgaization. Cardiovascular diseases (CVDs) [internet]. cited 2017 May 17. https://www.who.int/news-room/fact-sheets/detail/cardiovascular-diseases-(cvds)
- Stefanadis C, Antoniou CK, Tsiachris D, et al. Coronary atherosclerotic vulnerable plaque: current perspectives. J Am Heart Assoc. 2017;6:3.
- Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017;377(12):1119–1131.
- Australian Institute of Health and Welfare. Deaths in Australia. cited 2019 Jul 17. https://www.aihw.gov.au/reports/life-expectancy-death/deaths-in-australia/contents/age-at-death
- Kyaw T, Tay C, Khan A, et al. Conventional B2 B cell depletion ameliorates whereas its adoptive transfer aggravates atherosclerosis. J Immunol. 2010;185(7):4410–4419.
- Ait-Oufella H, Herbin O, Bouaziz JD, et al. B cell depletion reduces the development of atherosclerosis in mice. J Exp Med. 2010;207(8):1579–1587.
- Kyaw T, Tay C, Hosseini H, et al. Depletion of B2 but not B1a B cells in BAFF receptor-deficient ApoE mice attenuates atherosclerosis by potently ameliorating arterial inflammation. PLoS One. 2012;7(1):e29371.
- Sage AP, Murphy D, Maffia P, et al. MHC Class II-restricted antigen presentation by plasmacytoid dendritic cells drives proatherogenic T cell immunity. Circulation. 2014;130(16):1363–1373.
- Tay C, Liu YH, Hosseini H, et al. B-cell-specific depletion of tumour necrosis factor alpha inhibits atherosclerosis development and plaque vulnerability to rupture by reducing cell death and inflammation. Cardiovasc Res. 2016;111(4):385–397.
- Tay C, Liu Y-H, Kanellakis P, et al. Follicular B cells promote atherosclerosis via T cell-mediated differentiation into plasma cells and secreting pathogenic immunoglobulin G. Arterioscler Thromb Vasc Biol. 2018;38(5):e71–e84.
- Kyaw T, Tay C, Krishnamurthi S, et al. B1a B lymphocytes are atheroprotective by secreting natural IgM that increases IgM deposits and reduces necrotic cores in atherosclerotic lesions. Circ Res. 2011;109(8):830–840.
- Chen M, Lin X, Liu Y, et al. The function of BAFF on T helper cells in autoimmunity. Cytokine Growth Factor Rev. 2014;25(3):301–305.
- Zouggari Y, Ait-Oufella H, Bonnin P, et al. B lymphocytes trigger monocyte mobilization and impair heart function after acute myocardial infarction. Nat Med. 2013;19(10):1273–1280.
- Thompson N, Isenberg DA, Jury EC, et al. Exploring BAFF: its expression, receptors and contribution to the immunopathogenesis of Sjogren’s syndrome. Rheumatology (Oxford). 2016;55(9):1548–1555.
- Kim DH, Do MS. BAFF knockout improves systemic inflammation via regulating adipose tissue distribution in high-fat diet-induced obesity. Exp Mol Med. 2015;47:e129.
- Kyaw T, Cui P, Tay C, et al. BAFF receptor mAb treatment ameliorates development and progression of atherosclerosis in hyperlipidemic ApoE(-/-) mice. PLoS One. 2013;8(4):e60430.
- Tsiantoulas D, Sage AP, Goderle L, et al. B cell-activating factor neutralization aggravates atherosclerosis. Circulation. 2018;138(20):2263–2273.
- Nicoletti AM, Kenny CH, Khalil AM, et al. Unexpected potency differences between B-Cell-Activating Factor (BAFF) antagonist antibodies against various forms of BAFF: trimer, 60-Mer, and membrane-bound. J Pharmacol Exp Ther. 2016;359(1):37–44.
- Hong J, Maron DJ, Shirai T, et al. Accelerated atherosclerosis in patients with chronic inflammatory rheumatologic conditions. Int J Clin Rheumatol. 2015;10(5):365–381.
- Samoud-El Kissi S, Galai Y, Sghiri R, et al. BAFF is elevated in serum of patients with psoriasis: association with disease activity. Br J Dermatol. 2008;159(3):765–768.
- Nakayamada S, Tanaka Y. BAFF- and APRIL-targeted therapy in systemic autoimmune diseases. Inflamm Regen. 2016;36:6.
- Zhou B, Zhang H, Su X, et al. Therapeutic effects of a novel BAFF blocker on arthritis. Signal Transduct Target Ther. 2019;4:19.
- Theodorou E, Nezos A, Antypa E, et al. B-cell activating factor and related genetic variants in lupus related atherosclerosis. J Autoimmun. 2018;92:87–92.
- Rihacek M, Bienertova-Vasku J, Valik D, et al. B-cell activating factor as a cancer biomarker and its implications in cancer-related cachexia. Biomed Res Int. 2015;2015:792187.
- DeFuria J, Belkina AC, Jagannathan-Bogdan M, et al. B cells promote inflammation in obesity and type 2 diabetes through regulation of T-cell function and an inflammatory cytokine profile. Proc Natl Acad Sci U S A. 2013;110(13):5133–5138.
- McWilliams EM, Lucas CR, Chen T, et al. Anti-BAFF-R antibody VAY-736 demonstrates promising preclinical activity in CLL and enhances effectiveness of ibrutinib. Blood Adv. 2019;3(3):447–460.
- Schuepbach-Mallepell S, Das D, Willen L, et al. Stoichiometry of heteromeric BAFF and APRIL cytokines dictates their receptor binding and signaling properties. J Biol Chem. 2015;290(26):16330–16342.
- Vigolo M, Chambers MG, Willen L, et al. A loop region of BAFF controls B cell survival and regulates recognition by different inhibitors. Nat Commun. 2018;9(1):1199.